MAOB and Parkinson disease: Safinamide is a highly selective, reversible monoamine oxidase B (MAO-B) inhibitor that also reduces glutamate release (Müller 2018), and the phase 3 SETTLE study demonstrated the efficacy and safety of safinamide as add-on to levodopa in PD patients with motor fluctuations (Schapira et al. 2017).